CD8A and neoplasm: In fact, NLR, an expression of the immunosurveillance capacity of the host, the presence of higher levels of CD8 + in the tumor microenvironment, as an index of a patient’s better immune-response, and PD-L1 expression, indicating the tumor’s intrinsic immune-escape capability and consequently also the TME CD8 + T cells level, source of cytokines such as interferon gamma that induced the expression of PD-L1 [28, 29], mirrored some crucial aspects of the tumor/immunity interaction which, if considered together, better select LAGC patients who will benefit most from NAD-CT treatment.